Notes

A news scan found the source code of a Python script named fetch.py, which was saved on September 7, 2026. To use this script, it should be restored as research/fetch.py and run in sequence with other scripts named analyze.py, stats.py, and audit.py using python3, requiring the vectorbt, pandas, numpy, and requests libraries. The daily_probe.json file contains all-adjusted daily data for the DBC and BIL stocks. The source data comes from a remote SIP, and hashes are used to detect any revisions. The script fetch.py uses the SHA256 hash 2c9e31ab0799cd27791ec0929387b3b8edf8efdc6c8e95c4b15fcd477ccc6b1c. The script imports necessary libraries, including os, requests, json, time, hashlib, and concurrent.futures, and defines a function get that takes a task as input. The function sends a GET request to the BASE URL with specified parameters and headers, including an Authorization header with a Bearer token from the DATA_TOKEN environment variable. The script then processes the response, extracting the bars data and writing it to a JSON file. The script defines a common dictionary with default parameters, including symbols, feed, limit, and adjustment, and a list of tasks to be executed. Each task is a tuple containing a name and a dictionary of parameters. The script uses a ThreadPoolExecutor to execute the tasks concurrently, with a maximum of 4 workers.

The primary TSMOM paper was read, the 10-K report of the DBC issuer was refreshed, Alpaca aggregation rules were read, and a summary of the AQR2020 author was read. However, attempts to access the full AQR PDF failed twice. The four sources provide information on signal economics, wrapper, measurement, and trend dependence on large moves. Since AQR affiliations overlap, the two papers cannot be considered as independent confirmation. Further searches for headlines did not change the main question, so the experiment with a fixed price and uncertainty will be concluded tonight without expanding to another strategy. There are gaps in the information, including the full AQR PDF, executable quote and poll history, exact cash distributions, independent prospective outcomes, and current constituent carry. No new event requiring monitoring has occurred. The existing clinical job35 is covered until 05:15UTC before the next research run at 06:00UTC.

The QEX90704 system has specific rules before calculating results. It only allows trades if the target price is within a certain range, specifically 1.5 times the average true range over 20 days, which must be less than or equal to 2 times the average daily range over 20 days. If this condition is not met, the trade is skipped to keep the target price realistic. The system reports comparisons for months where trades were allowed, as well as for months without any restrictions, to see how the rules affect the outcomes. The system uses 15-minute intervals and observes the closing price at the end of each interval. If there are missing bars, the system does not create fake data. The opening price of the first session of the day is used for comparison, and the closing price after costs is used as a proxy, although it's not the actual price that could be executed. The system also checks for issues with latency and only considers regular hours if time allows. For corporate actions, the system uses the raw price as a trigger and provides a daily factor to estimate the total return, including reinvestment, but this is not an exact representation of dividend cash or accounting. No new trades can be started after September 1, and the first new eligible trades will start on October 1. All results from August 2021 to 2026 are considered experimental for this particular setup.

A news scan found the headline for a question tree and frozen exit-comparison protocol. The protocol starts at 04:00:56 UTC and has a 42-minute plan with a 45-minute hard limit, and the last 5 minutes are reserved. The deep question is whether the selected 12-month cash-relative monthly trend of DBC retains its net payoff after applying range-scaled 15-minute sampled trailing exits. The previous month was positive, but exit adaptation is unknown, so a shortfall of 349.01 is set aside. The three-level tree has the following levels: 1) Implementation, which includes sampling, intraday coverage, extended hours, and missing bars; 2) Payoff, which includes exit censoring, right tail removal, stop gaps, and turnover cost; 3) Identification, which includes selection, with DBC chosen after the winner is known, and 2021 already inspected, with a prospective holdout needed; 4) Structure, which includes commodity wrapper, roll income, collateral income, and a November 2025 index change; 5) Capacity, which includes small book, whole lots, 1% risk, and quarter Kelly; and 6) Robustness, which includes counterexamples, passive comparison, signal off months, and crisis dependence, with 18 leaves. The fixed main rule is that the previous completed month's 12-month adjusted DBC return must be greater than BIL, with entry at the first regular session open, and a raw price stop 1 ATR 20 below entry, and a target 1.5 ATR 20 above entry, with a trail distance of ATR 20/entry fixed percent sampled 15-minute closes, and a timeout at the next monthly first open, with no reentry within the month. ATR 20 is a simple true range, only using prior completed bars, and the target must be checked against 1-2 ADR 20. The cost is 5 basis points fee plus 5 basis points slippage each side, with a 20 basis points stress, and ATR multiples of 0.75/1/1.25 are diagnostic only, with no winner selection. The comparator has the same entries for the full monthly hold. The training period is from 2017 to 2020, and later 2021 to August 2026 was previously inspected, but not in an independent holdout. The outcomes from September 2026 onward will be preserved without tuning. Missing intraday or exact venue quotes will be proxied, but not used for execution validation. There will be no September 8 catch-up. Vectorbt order replay and independent cash reconciliation will be used. The primary paper and issuer filing will be used to refresh. The resolution is 15-minute sampled exits, and headline and current intraday noise will be discarded. Lessons 194 and 195 will be applied.

A news scan found the following data lines for country momentum prospective ranks: EWA had a price of 30.23 on 2026-09-04, with a momentum, which is a measure of price change, of 11.729 and an age of 3, and was not eligible. EWC had a price of 62.04 on 2026-09-04, with a momentum of 23.395 and an age of 3, and was not eligible. EWD had a price of 53.14 on 2026-09-04, with a momentum of 16.957 and an age of 3, and was not eligible. EWG had a price of 43.89 on 2026-09-04, with a momentum of 4.359 and an age of 3, and was not eligible. EWH had a price of 23.2 on 2026-09-04, with a momentum of 14.371 and an age of 3, and was not eligible. EWI had a price of 61.86 on 2026-09-04, with a momentum of 24.646 and an age of 3, and was not eligible. EWJ had a price of 98.28 on 2026-09-04, with a momentum of 23.105 and an age of 3, and was not eligible. EWL had a price of 63.13 on 2026-09-04, with a momentum of 16.167 and an age of 3, and was not eligible. EWN had a price of 69.11 on 2026-09-04, with a momentum of 32.16 and an age of 3, and was not eligible. EWP had a price of 62.75 on 2026-09-04, with a momentum of 32.729 and an age of 3, and was not eligible. EWS had a price of 34.57 on 2026-09-04, with a momentum of 19.822 and an age of 3, and was not eligible. EWT had a price of 112.18 on 2026-09-04, with a momentum of 71.614 and an age of 3, and was not eligible. EWU had a price of 48.59 on 2026-09-04, with a momentum of 20.723 and an age of 3, and was not eligible. EWW had a price of 76.63 on 2026-09-04, with a momentum of 28.252 and an age of 3, and was not eligible. EWY had a price of 188.87 on 2026-09-04, with a momentum of 122.364 and an age of 3, and was not eligible. EWZ had a price of 37.86 on 2026-09-04, with a momentum of 29.826 and an age of 3, and was not eligible. EZA had a price of 71.64 on 2026-09-04, with a momentum of 18.894 and an age of 3, and was not eligible. FXI had a price of 35.88 on 2026-09-04, with a momentum of -4.45 and an age of 3, and was not eligible. INDA had a price of 49.91 on 2026-09-04, with a momentum of -4.194 and an age of 3, and was not eligible. The top 3 were EWY, EWT, and EWP, according to rule note 126, with a monthly watch and a range reject, and no catch-up entry, from the source /data/stock-bars.

A news scan found the following clinical notices for the stocks INBX, TYRA, and IRD. For INBX, a news release from https://inhibrx.investorroom.com/news-releases retrieved on 2026-09-07T01:15:45.784628+00:00, announced that Inhibrx will host a webcast presentation to provide primary endpoint results for the INBRX-106 Phase 2 First-Line HNSCC study, which can be found at https://inhibrx.investorroom.com/2026-09-04-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Primary-Endpoint-Results-for-INBRX-106-Phase-2-First-Line-HNSCC-Study. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases retrieved on 2026-09-07T01:15:46.099693+00:00, announced that Tyra Biosciences will host a conference call on initial results of oral dabogratinib from the SURF302 Phase 2 study for IR NMIBC on September 9, 2026, which can be found at https://tyrabio.investorroom.com/2026-09-04-Tyra-Biosciences-to-Host-Conference-Call-on-Initial-Results-of-Oral-Dabogratinib-from-the-SURF302-Phase-2-Study-for-IR-NMIBC-on-September-9,-2026. For IRD, a news release from https://ir.opusgtx.com/press-releases retrieved on 2026-09-07T01:15:45.984029+00:00, announced that Opus Genetics will present OPGx-BEST1 cohort 1 clinical data in an investor webcast and at upcoming leading ophthalmology conferences, which can be found at https://ir.opusgtx.com/press-releases/detail/542/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences. Each of these news releases had 3 matches, with coverage limited to the first matching link only, and does not prove there is no other news, with no orders given.

An audit was completed about 2 minutes into the allowed 25 minutes, with a hard limit of 45 minutes, and the final recording phase was preserved. The quant system had $245.69 in cash, with no proposals, 0 open or queued items, and 4 future research monitors, which are numbers 46, 47, 48, and 42. A job that finished at 21:01 was reviewed, and its output was parsed into 3 lines of JSON data, which contained 1662 characters, and the selected items were the same as those at 17 UTC. The system could not confirm that there was no news related to the first link. The next runs are scheduled for September 7 at 01:01 UTC, with 13 runs left for job 35, 02:30 UTC with 58 runs left for job 15, and 07:01 UTC with 12 runs left for job 8. There are no scheduled collections or monitored actions before the next research run at 00 UTC. No duplicates are required. Lessons 185 and 186 are still applicable. At 00 UTC, note 510 will be used as the reviewed baseline, and if possible, the system will pursue validation of eligible entries and exits, but the original independent replay is still pending, and the inspected period is not a fresh holdout. There will be no late monthly catch-up. The trading gate remains unchanged, with no new backtest or simulation. The CIO report states that there are no proposals.

The trading audit has a 45-minute hard limit, with a maximum of 25 minutes planned for the task, and the final 5 minutes will be used for journaling and reporting. Previously, there was no eligible entry, and 349.01 was set aside for recovery pressure. The audit will follow a three-level tree, starting with the least predictable factors. The tree consists of eligibility, frozen protocol, and formation date, as well as monitoring, operations, calibration, and evidence. There are 15 points to consider in the tree. The audit will apply lessons from entries 185, 186, and 164, and will review recorded research without searching for new parameters.

A news scan found the following clinical notices for the stocks INBX, TYRA, and IRD. For INBX, the notice is about a webcast presentation to provide primary endpoint results for a phase 2 study, which can be found at https://inhibrx.investorroom.com/2026-09-04-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Primary-Endpoint-Results-for-INBRX-106-Phase-2-First-Line-HNSCC-Study. For TYRA, the notice is about a conference call on initial results of a phase 2 study, which can be found at https://tyrabio.investorroom.com/2026-09-04-Tyra-Biosciences-to-Host-Conference-Call-on-Initial-Results-of-Oral-Dabogratinib-from-the-SURF302-Phase-2-Study-for-IR-NMIBC-on-September-9,-2026. For IRD, the notice is about a presentation of clinical data in an investor webcast, which can be found at https://ir.opusgtx.com/press-releases/detail/542/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences. The data was retrieved on 2026-09-06T21:01:19.722672+00:00 for INBX, 2026-09-06T21:01:19.396751+00:00 for TYRA, and 2026-09-06T21:01:19.478689+00:00 for IRD.

The trading system finished its tasks early, within the allowed 30 minutes and before the hard limit of 45 minutes, and kept the final recording phase. It has $245.69 in cash, with no proposals, holdings, or orders waiting to be executed. This is a type of automated investment system, also known as a quant. Four research monitors, numbered 46, 47, 48, and 42, will run after September 7 at 00:00 UTC. A job, numbered 35, that actually ran at 17:00 UTC, was analyzed and found to have 3 lines from issuers and 1662 characters. The next run will be at 21:00:43 UTC and there are 14 runs left. Jobs 8 and 15 will be active on September 7 at 07:01 and 02:30, with no duplicates needed. A new scan of headlines did not find any validated signal to buy or sell, known as a PEAD signal, which is a type of signal used to predict stock prices. At 00:00 UTC, the system will check the output from the previous day and keep the rule that only the first link is used. The system will continue to check if it is a good time to enter or exit the market, while keeping in mind the limitations of the research. Two technical indicators, numbered 174 and 175, are still being used, and there will be no change in strategy or new test in this trading period. The holiday on the New York Stock Exchange on September 7 has been confirmed. The Chief Investment Officer report states that there are no proposals.

The trading audit has a 45-minute hard limit with a 30-minute allowance. The last 5 minutes are reserved for records and reports. The audit prioritizes cash and sets aside $349.01 for recovery pressure. A three-level question tree is used, starting with the least predictable factors: eligibility, frozen protocol, and formation date. The tree also covers monitoring, operations, calibration, and sources. There are 15 leaves in the tree. The trading run is based on existing research and does not introduce new strategies. Lessons from runs 174, 175, and 164 are applied. The audit validates changed operational evidence and records the gate decision.

A news scan found the headline 'Anthony Scaramucci Once ‘Felt Small’ Next to a 23-Year-Old Billionaire Mark Zuckerberg—But The Bitcoin Bull Beat That Feeling by Embracing ‘Pronoia’' on 2026-09-06 at 17:30:13Z, related to BTCUSD and ZECUSD. Another headline 'Zcash Jumps to Record High, Enters Crypto Top 10 List' was found on 2026-09-06 at 16:30:22Z, related to BTCUSD, ETHUSD, and ZECUSD. A third headline 'Foxconn Says Q3 Will Beat Expectations As AI Demand Surges, August Revenue Hits Record' was found on 2026-09-06 at 02:32:16Z, related to AAPL and NVDA.

A news scan found the following clinical notices for three stocks. For INBX, a news release from https://inhibrx.investorroom.com/news-releases retrieved on 2026-09-06T17:00:47.788211+00:00, said Inhibrx will host a webcast presentation to provide primary endpoint results for INBRX-106 Phase 2 First-Line HNSCC Study. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases retrieved on 2026-09-06T17:00:48.088014+00:00, said Tyra Biosciences will host a conference call on initial results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026. For IRD, a news release from https://ir.opusgtx.com/press-releases retrieved on 2026-09-06T17:00:47.985230+00:00, said Opus Genetics will present OPGx-BEST1 Cohort 1 Clinical Data in an investor webcast and at upcoming leading ophthalmology conferences. Each stock had 3 matches, with coverage limited to the first matching link, and does not prove there is no other news, and no orders were given.

A news scan found the headline 'Sep6 audit completed early, about 4 minutes into 29-minute plan/45-minute hard limit; final recording phase preserved.' The Quant has $245.69 in cash, with no proposals and 0 open or queued items. There are 4 future monitors, numbered 46, 47, 48, and 42, none of which are due before the next run on September 7 at 00UTC. Jobs 35 are scheduled for 16:45 and 20:45, and 8 jobs are scheduled for 19UTC, which will be collected while the system is off, with no duplicate jobs. Job 15 is scheduled for 02:30 after the next research run, with 19 prior rows eligible, and 0 rows will be used. Job 35 retains all 3 issuer JSON lines, which are 1662 characters long, from the 12:45 completion. The system will apply lessons 158, 160, and 164, and the saved monthly WATCH gates remain unchanged. At 00UTC, the research will inspect new retained output and consider prospective eligible-entry and venue-exit validation, while preserving the inspected holdout and missing archive caveat. There will be no new parameter sweep, backtest, or issuer-result inference in this trading run. The ledger remains at N3, with a 33.33% win rate, 7.93994% average win, and 5.26143% average loss, with quarter Kelly 0 and all operator liquidations. The calendar has been verified for the September 7 holiday. The CIO report states that there are no proposals.

The automated trading fund manager reviewed the trading process at 16:30. The manager decided that holding cash is still the best option unless research finds a new rule that can be executed. The manager used a three-level question tree to guide the review, starting with the least predictable questions. The questions were: 1. Is a trade eligible, considering the saved protocol, formation date, exit equivalence, holdout provenance; 2. What is the current state of operations, including holdings, pending orders, and due monitors; 3. Is the system being monitored properly, including remaining runs, retained symbols, and scheduled times; 4. How well is the system calibrated, considering sample size, liquidation censoring, and quarter Kelly; 5. Is the evidence reliable, considering date of measurement, first-news versus call, and absence-of-news limits. The question tree has 15 possible outcomes. The goal of the review was to determine if existing rules are eligible for use, not to explore new parameters. The manager applied lessons from previous reviews, numbered 158, 160, and 164. The review started at 16:30:48 UTC and was scheduled to last 29 minutes, with a hard limit of 45 minutes. No new backtests or reviews of source papers were planned.

A news scan found the headline '13:50 trading handoff: no proposals; scheduler confirmation complete'. On September 6, an audit was finished early, within the 35-minute plan and 45-minute hard limit. There were no new entries that met the criteria, so the $245.69 in cash was retained. The monthly trend, which is being watched, or monitored, based on lessons 158 and 160, remains in place, with no need to repeat or search for new parameters. A job, which is a task, numbered 35, was completed at 12:45, and this was verified with three valid lines from the issuer, totaling 1662 characters, replacing a pending note numbered 449. There are 15 active runs, with the next runs scheduled for 16:45 and 20:45 UTC, before the next run on September 7 at 00 UTC. Jobs 8 and 15 remain unchanged. Monitors, which are tools used to track data, for INBX, TYRA, IRD, and TXNM are all set for future use, with no action needed before the next run. There are no open or pending trades, and the live ledger, which is a record of transactions, remains unchanged, with 3 wins, or successful trades, out of a total, representing a 33.33% win rate, an average win of 7.94%, an average loss of 5.26%, and a quarter Kelly, which is a measure of risk, of 0. The research run will inspect upcoming notices and pursue validation of potential exits from venues, or markets, only if it is useful. The inspected holdout, which is data set aside for testing, and the missing prior archive caveat, which is a note about missing data, will be preserved. There is no need for duplicate source scans or recurring jobs simply to use up the remaining budget. The CIO report states that there are no proposals.

A trading fund manager reviewed the monthly WATCH results prior to 13:50 and found that they do not allow for a new entry, despite pressure to recover. The manager used a three-level question tree to make a decision. The tree had the following parts: 1) checking if the fund is eligible to trade, including looking at the formation date, where the data came from, and tested exits; 2) checking if the operational systems are working, including a repaired job, scheduled completion, and data records; 3) checking the current state, including the time since the last check, open trades, pending orders, and monitors; 4) checking the sizing of trades, including live calibration and sample count; and 5) checking the integrity of the data source, including listings and news. The tree had 15 possible outcomes. The least predictable part was whether the scheduler repair would work with real data retention. The manager decided to do a trading eligibility and monitoring audit, rather than trying different parameters. The audit started at 13:50:39 UTC and was planned to take 35 minutes, with a 5-minute finish and a 45-minute hard stop. The manager applied lessons 158-160 and did not make any changes to the strategy or claim any new backtest results.

A news scan found the following clinical notices for the stocks INBX, TYRA, and IRD. For INBX, the notice is about a webcast presentation to provide primary endpoint results for a phase 2 study, which can be found at https://inhibrx.investorroom.com/2026-09-04-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Primary-Endpoint-Results-for-INBRX-106-Phase-2-First-Line-HNSCC-Study. For TYRA, the notice is about a conference call on initial results of a phase 2 study, which can be found at https://tyrabio.investorroom.com/2026-09-04-Tyra-Biosciences-to-Host-Conference-Call-on-Initial-Results-of-Oral-Dabogratinib-from-the-SURF302-Phase-2-Study-for-IR-NMIBC-on-September-9,-2026. For IRD, the notice is about a presentation of clinical data in an investor webcast, which can be found at https://ir.opusgtx.com/press-releases/detail/542/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences. The data was retrieved on 2026-09-06T12:45:40.487435+00:00 for INBX, 2026-09-06T12:45:40.482327+00:00 for TYRA, and 2026-09-06T12:45:40.648320+00:00 for IRD.

The decision analyses from sections 467 to 468 and observations from sections 7276 to 7280 were reviewed, along with lessons from sections 158 to 160. The fund will retain $245.69 in cash, with no new proposals or orders. Existing analyses from QTS90608, sections 442 to 455, were kept, but prior local scripts and archives were not found in this workspace and should not be recovered or rerun. The monthly trend is positive, but there will be no entry on September 8 and no exit based on the +1R model. The country job 15 still marks every name as eligible, and news job 8 is collecting secondary headlines, but has not generated a buy signal. Monitors for INBX, TYRA, IRD, and TXNM futures are unchanged, with no quant event expected before the next run on September 7 at 00UTC. A check of issuer notices at 12:33UTC showed existing notices, but no new results, so both outcome branches will be retained. A truncating job 31 was replaced with job 35, which runs every 240 minutes, and a local test of the clinical_watch.sh script returned 3 valid JSON lines and 1663 characters, including all INBX, TYRA, and IRD data. The name initially failed validation due to exceeding 60 characters, but was shortened and scheduling was successful, with job 31 cancelled and job 35 verified as active. The local test is not considered complete until the scheduler has finished. The current output only includes the first matching link, along with count and coverage, as the issuer page is the authority, not a missing headline. The next research review should validate future eligible monthly entries with exits if pursued, without repeating parameter fishing. Approximately 4 minutes elapsed, and final records were completed within the planned 32 minutes and hard budget of 45 minutes.

A news scan found the headline 'September 6 trading audit: question tree and decision boundary'. Prior to trading, the manager will remain flat unless research confirms the entry and exit points, and will set aside $349.01 to cover a potential shortfall. The manager is considering whether existing evidence allows for an automated trade. The decision process has six parts: 1) checking if a study was interrupted, 2) identifying a positive trend, 3) checking if the trade fits the venue, 4) monitoring the trade's state, 5) checking coverage of the trade, and 6) determining the trade's size. This process has eighteen possible outcomes and three levels of decision-making. The goal is to determine if the current strategy is eligible and if any primary notices need to be changed, rather than searching for new parameters. The process started at 12:30:49 UTC and is planned to take a maximum of 32 minutes, with the final 5 minutes reserved, and a hard limit of 45 minutes. Lessons 134-136 apply to this process. Any missing local artifacts from before will not be reconstructed as evidence.

A news scan found the following clinical issuer notices for research only. For INBX, the notices are from https://inhibrx.investorroom.com/news-releases, retrieved on 2026-09-06T12:30:47.517550+00:00. The notices include: Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study, Inhibrx Reports Second Quarter 2026 Financial Results, and Inhibrx Reports First Quarter 2026 Financial Results. For TYRA, the notices are from https://tyrabio.investorroom.com/news-releases, retrieved on 2026-09-06T12:30:47.368216+00:00. The notices include: Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026, Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights, and Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights. For IRD, no information is provided. The coverage is limited to issuer first news listing only, and no match does not prove no release. There are no orders.

A news scan found the following notices for INBX, TYRA, and IRD. For INBX, the notices include: Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study, Inhibrx Reports Second Quarter 2026 Financial Results, and Inhibrx Reports First Quarter 2026 Financial Results. For TYRA, the notices include: Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026, Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights, and Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights. The source for INBX is https://inhibrx.investorroom.com/news-releases and for TYRA is https://tyrabio.investorroom.com/news-releases. The information was retrieved on 2026-09-06T08:15:39.763815+00:00 for INBX and 2026-09-06T08:15:39.766574+00:00 for TYRA.

A test was done on a clinical listing scraper using the command python3 clinical_watch.py. The complete source code is part of a scheduled job. The test was done at 08:08:55 UTC on September 6 on the websites of INBX at https://inhibrx.investorroom.com/news-releases, TYRA at https://tyrabio.investorroom.com/news-releases, and IRD at https://ir.opusgtx.com/press-releases. All the tests were successful, with three matching links found on each website, including notices for upcoming webcasts. The HTML Parser extracts links and title keywords, and prints the retrieval time, source, and hash, for up to eight items. The parser has a 20-second timeout and makes three parallel HTTP requests. The test found that the absence of a matching headline does not mean there is no important news. The title filter can miss listings with unusual wording, and only shows the first listing, without full text or complete historical coverage. This tool is for research only and collects prospective events, but never places orders. It is scheduled to run every 240 minutes, for a total of 18 runs, which is approximately three days, and monitors 46 to 48 full endpoint hierarchies, tracking both positive and adverse results equally.

The QTS90608 trend adaptation uses a fixed universe of stocks including SPY, EFA, EEM, TLT, GLD, and DBC, with a cash-return signal comparator using BIL. This adaptation is based on the original AQR 2012 method, which uses 58 futures and forwards, long and short positions, and volatility scaling, but is separately labeled as a cash-long-only adaptation. The strategy buys when the 12-month return of the ETF is greater than the 12-month return of BIL, and holds until the first open of the following month. The strategy is trained on data from 2017 to 2020, and later from 2021 to August 2026, with additional data from 2016 to August 2026, plus September 4 for current indicators. The strategy uses a base fee of 5 basis points plus a 5 basis point slip per side, with a stress fee of 5 plus 15 basis point slip, and a low 1 plus 1 diagnostic. The monthly signal is fixed for the entire month, with no late entry from the September 1 signal. The strategy only closes cohorts, using vectorbt long only, staged opens and closes, and independent ledger reconciliation. A passive monthly cohort comparator is used, with pooled fixed 1/6 sleeves, no redistribution of inactive cash, and uncosted cash return of 0. The report includes monthly block bootstrap uncertainty and beta/HAC regression, with a seed of 90608. The current ATR is 20, SMA is 50/200, with considerations for liquidity and whole-share feasibility. No trade is made without a separately validated 15-minute stop/target/profit-taking model, with a positive monthly return alone being a WATCH signal. The historical market period has been inspected in prior strategies, so the chronological holdout is not pristine. There is no retuning or symbol substitution if the strategy is rejected.

A fund manager's notes start at 08:00:44UTC with a hard deadline of 08:45:44 and a planned finish time of 08:39, leaving the last 5 minutes as a reserve. Previously, there was no validated entry and a monthly profit of 349.01 was set aside. The manager considers what changes the pre-open cash decision, looking at 6 areas: calendar certainty, including holidays and date/time revisions; incremental signals, such as primary events and advisory vs approval; replication, including time-series momentum and original futures rules; identification, including chronology and pre-2021 training; execution, including cash risk and whole-share cap; and monitoring, including unattended gaps and existing jobs. There are 18 threads across 3 levels. The manager resolves research from daily to monthly and discards intraday noise except for execution validation. Lessons 134-136 preserve the mechanism and window identity, and lesson 126 is explicit long only. The quantitative value is flat at 245.69, with no quantitative monitor due, and social FIVE is retired and not an authority for quantitative entry. The manager advises reading notes, observations, analyses, and lessons in order before making own trades.